Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Secondary Hyperparathyroidism
Conditions
Secondary Hyperparathyroidism
Trial Timeline
Jul 1, 2014 → Feb 1, 2015
NCT ID
NCT02216656About Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493 is a phase 2 stage product being developed by Kyowa Kirin for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02216656. Target conditions include Secondary Hyperparathyroidism.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02216656 | Phase 2 | Completed |
Competing Products
20 competing products in Secondary Hyperparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| KHK7580 + KRN1493 | Kyowa Kirin | Phase 2/3 | 65 |
| KHK7580 | Kyowa Kirin | Phase 1 | 33 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| Cinacalcet HCl | Kyowa Kirin | Approved | 85 |
| KHK7580 + Cinacalcet Hydrochloride | Kyowa Kirin | Phase 3 | 77 |
| dirucotide + Placebo | Eli Lilly | Phase 2/3 | 65 |
| dirucotide | Eli Lilly | Phase 2/3 | 65 |
| Paricalcitol + Calcitriol | AbbVie | Pre-clinical | 23 |
| paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo | AbbVie | Phase 3 | 77 |
| Paricalcitol + Calcifediol | AbbVie | Approved | 85 |
| Paricalcitol + Darbepoetin alfa | AbbVie | Approved | 85 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273 | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |